Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

53 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immunogenicity of an Escherichia coli-produced bivalent human papillomavirus vaccine under different vaccination intervals.
Yu XJ, Li J, Lin ZJ, Zhao H, Lin BZ, Qiao YL, Hu YM, Wei LH, Li RC, Huang WD, Wu T, Huang SJ, Li CG, Pan HR, Zhang J. Yu XJ, et al. Among authors: lin bz, lin zj. Hum Vaccin Immunother. 2020 Jul 2;16(7):1630-1635. doi: 10.1080/21645515.2020.1761202. Epub 2020 Jun 16. Hum Vaccin Immunother. 2020. PMID: 32544361 Free PMC article. Clinical Trial.
Lot-to-lot consistency study of an Escherichia coli-produced bivalent human papillomavirus vaccine in adult women: a randomized trial.
Su YY, Lin BZ, Zhao H, Li J, Lin ZJ, Qiao YL, Wei LH, Hu YM, Li RC, Zhuang SJ, Sun G, Zheng ZZ, Huang SJ, Wu T, Zhang J, Pan HR, Li CG. Su YY, et al. Among authors: lin bz, lin zj. Hum Vaccin Immunother. 2020 Jul 2;16(7):1636-1644. doi: 10.1080/21645515.2019.1691413. Epub 2019 Nov 26. Hum Vaccin Immunother. 2020. PMID: 31770068 Free PMC article. Clinical Trial.
Safety and immunogenicity of an Escherichia coli-produced bivalent human papillomavirus type 6/11 vaccine: A dose-escalation, randomized, double-blind, placebo-controlled phase 1 trial.
Mo ZJ, Bi ZF, Sheng W, Chen Q, Huang T, Li MQ, Cui XL, Wangjiang YH, Lin BZ, Zheng FZ, Sun G, Li YF, Zheng Y, Zhuang SJ, Su YY, Pan HR, Huang SJ, Wu T, Zhang J, Xia NS. Mo ZJ, et al. Among authors: lin bz. Hum Vaccin Immunother. 2022 Nov 30;18(6):2092363. doi: 10.1080/21645515.2022.2092363. Epub 2022 Jul 14. Hum Vaccin Immunother. 2022. PMID: 35834812 Free PMC article. Clinical Trial.
Efficacy, safety, and immunogenicity of an Escherichia coli-produced Human Papillomavirus (16 and 18) L1 virus-like-particle vaccine: end-of-study analysis of a phase 3, double-blind, randomised, controlled trial.
Zhao FH, Wu T, Hu YM, Wei LH, Li MQ, Huang WJ, Chen W, Huang SJ, Pan QJ, Zhang X, Hong Y, Zhao C, Li Q, Chu K, Jiang YF, Li MZ, Tang J, Li CH, Guo DP, Ke LD, Wu X, Yao XM, Nie JH, Lin BZ, Zhao YQ, Guo M, Zhao J, Zheng FZ, Xu XQ, Su YY, Zhang QF, Sun G, Zhu FC, Li SW, Li YM, Pan HR, Zhang J, Qiao YL, Xia NS. Zhao FH, et al. Among authors: lin bz. Lancet Infect Dis. 2022 Dec;22(12):1756-1768. doi: 10.1016/S1473-3099(22)00435-2. Epub 2022 Aug 26. Lancet Infect Dis. 2022. PMID: 36037823 Clinical Trial.
Immunogenicity noninferiority study of 2 doses and 3 doses of an Escherichia coli-produced HPV bivalent vaccine in girls vs. 3 doses in young women.
Hu YM, Guo M, Li CG, Chu K, He WG, Zhang J, Gu JX, Li J, Zhao H, Wu XH, Lin B, Lin ZJ, Yao XM, Li YF, Wei F, Huang Y, Su YY, Zhu FC, Huang SJ, Pan HR, Wu T, Zhang J, Xia NS. Hu YM, et al. Sci China Life Sci. 2020 Apr;63(4):582-591. doi: 10.1007/s11427-019-9547-7. Epub 2019 Jun 21. Sci China Life Sci. 2020. PMID: 31231780 Free PMC article.
Naturally acquired HPV antibodies against subsequent homotypic infection: A large-scale prospective cohort study.
Yao X, Chen W, Zhao C, Wei L, Hu Y, Li M, Lin Z, Lin B, Liu X, Hong Y, Li Q, Pan Q, Zhang X, Li M, Zhao Y, Zhang L, Xu H, Hu F, Zhao J, Huang Y, Sheng W, Zheng Y, Hu S, Su Y, Huang S, Pan H, Zhao F, Qiao Y, Wu T, Zhang J, Xia N. Yao X, et al. Lancet Reg Health West Pac. 2021 Jul 16;13:100196. doi: 10.1016/j.lanwpc.2021.100196. eCollection 2021 Aug. Lancet Reg Health West Pac. 2021. PMID: 34527987 Free PMC article.
53 results